Augmenting immunogenicity workflows with AI and real-world evidence: failure points, tools, and a closed-loop operational blueprint.

Immunogenicity undermines the safety and effectiveness of biologics and emerging modalities. Routine workflows are constrained by drug/target interference in binding assays, matrix and dilution biases in functional assays, fragile cellular/innate rea…

Preview only. Read the full abstract at the source